AstraZeneca's Prilosec OTC suit deemed "frivolous"
This article was originally published in The Tan Sheet
Executive SummaryAstraZeneca must pay Dr. Reddy's attorneys' fees for a patent infringement case, says Judge Colleen McMahon of the U.S. District Court for the Southern District of New York. She writes in a March 30 1decision that AstraZeneca lacked evidence that Dr. Reddy's abbreviated new drug application for a Prilosec OTC equivalent infringed its patents. "I certainly hope that this ruling chills the sort of unreasonable, frivolous, anti-competitive, anti-consumer litigation in which plaintiffs here engaged," McMahon writes. Dr. Reddy's won the suit in March 2009, but did not launch its generic omeprazole capsule until late 2009 (2"The Tan Sheet" Dec. 21, 2009, In Brief)
You may also be interested in...
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
How do the EU’s new MDR cybersecurity guidelines expand on the MDR and fit into the myriad other software-related guidance documents the medtech industry has to consider?